Evidence map›Paper›PMID 37352296›Full record

Trial reportPloS one2023

Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study).

Kenneth Ngure, Barbara A Friedland, Daniel W Szydlo, Sarah T Roberts, Morgan Garcia, Lisa Levy, Carolyne A Akello, Krishnaveni Reddy, Thesla Palanee-Phillips, Pippa Macdonald and 7 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 5 countries.

Kenneth NgureSchool of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
Barbara A FriedlandPopulation Council, Center for Biomedical Research, New York, NY, United States of America.
Daniel W SzydloStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Sarah T RobertsWomen's Global Health Imperative (WGHI), RTI International, Berkeley, California, United States of America.ORCID 0000-0002-3318-9781
Morgan GarciaFHI 360, Durham, North Carolina, United States of America.
Lisa LevyFHI 360, Durham, North Carolina, United States of America.
Carolyne A AkelloJohns Hopkins University Research Collaboration, Makerere University, Kampala, Uganda.
Krishnaveni ReddyWits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Thesla Palanee-PhillipsWits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Pippa MacdonaldWits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Bekezela SizibaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Lydia Soto-TorresNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Sybil HosekDepartment of Psychiatry, John Stroger Hospital of Cook County, Chicago, Illinois, United States of America.
Sharon L HillierDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Gonasagrie NairCentre for Medical Ethics and Law, Stellenbosch University, Stellenbosch, South Africa.
Connie CelumDepartment of Global Health, University of Washington, Seattle, WA, United States of America.
Ariane van der StratenCenter for AIDS Prevention Studies, Dept of Medicine, University of California, San Francisco, San Francisco, California, United States of America.
University of the Witwatersrand · ZAFamily Health International 360 · USUniversity of Washington · USFred Hutch Cancer Center · USJohn H. Stroger, Jr. Hospital of Cook County · USMUJHU Research Collaboration · UGNational Institutes of Health · USPopulation Council · USRTI International · USStellenbosch University · ZAUniversity of California, San Francisco · USUniversity of Pittsburgh · USUniversity of Zimbabwe · ZW

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Immaculate Lillian Nankya · 1994 to 2026
$50.0M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
NIAID NIH HHS P30 AI036219NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

introductionAdolescent girls and young women (AGYW) in sub-Saharan Africa are disproportionately affected by the HIV epidemic and face an array of challenges using proven behavioral and biomedical prevention methods. To address the urgent need for expanding prevention options, we evaluated the baseline preferences of HIV prevention methods among participants enrolled in the MTN-034/REACH crossover trial along with their stated product preference prior to product initiation.

methodsAGYW aged 16-21 years were enrolled at 4 study sites: Cape Town and Johannesburg, South Africa; Kampala, Uganda; and Harare, Zimbabwe and randomly assigned to the sequence of using oral PrEP and the dapivirine ring for 6 months each, followed by a choice period in which they could choose either product (or neither) for an additional six months. Eligible AGYW were HIV-negative, not pregnant and using effective contraception for at least two months prior to enrollment. Descriptive statistics were used to summarize demographic and behavioral data while multinomial analysis was used to determine predictors of stated product preference (ring or oral PrEP).

resultsOf the 247 AGYW enrolled in REACH, 34% were aged 16-17 and 89% had a primary partner.The median age of sexual debut was 16 years and 40% had ever been pregnant. At screening, 35% of participants were diagnosed with a sexually transmitted infection (STI), 39% had an AUDIT-C score associated with harmful drinking and 11% reported intimate partner violence in the past 6 months. Overall, 28% of participants, had CESD-10 scores suggestive of depressive symptoms (≥12) in the past week. At baseline, similar proportions stated a preference for the ring and oral PrEP (38.1% and 40.5% respectively), with 19% of participants stating they preferred both products equally. Only study site was significantly associated with product preference (P<0.05) with AGYW from Johannesburg having higher odds of preferring the ring and those from Kampala having higher odds of preferring both options equally.

conclusionsWe successfully enrolled African AGYW with a clear unmet need for HIV prevention. The balanced preference between the two products suggests that multiple biomedical prevention options may be appealing to this age group and could address their prevention needs.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisAdolescentFemaleHumansPregnancyPyrimidinesSouth AfricaUgandaYoung AdultZimbabweAnti-HIV AgentsDapivirinePyrimidines

Identifiers

PMID37352296
PMCPMC10289422
OpenAlexW4381839159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.